UBS starts coverage of BioMarin stock with USD 88.00 target

Published on 10/17/2026 at 18:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 989.71 million, up 20.00 percent. BioMarin stock was USD 54.68 on October 16, 2026, down 2.44 percent versus prior close.

Analyst target and results date

UBS initiated BioMarin coverage with a USD 88.00 target on October 15, 2026.
Second-quarter revenue reached USD 989.71 million, up 20.00 percent year over year.
BioMarin stock was USD 54.68 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 2.44 percent versus the prior close.
BioMarin is scheduled to report earnings on October 26, 2026.

BMRN, US09061G1013, Illustration mit AI erstellt.

UBS Group initiated coverage of BioMarin Pharmaceutical with a Buy rating and a USD 88.00 price target on October 15, 2026, according to MarketBeat. Based on the latest USD 54.68 Nasdaq quote, the target stood 60.94 percent above the price. The last Nasdaq quote was USD 54.68 on October 16, 2026 at 4:00 p.m. EDT, down 2.44 percent versus the prior close.

Second-quarter revenue reaches USD 989.71 million

BioMarin reported second-quarter 2026 revenue of USD 989.71 million, a 20.00 percent year-over-year increase, while adjusted earnings per share came to USD 1.20 against a USD 0.95 consensus estimate, MarketBeat reported on October 14, 2026. Revenue exceeded the consensus estimate of USD 932.03 million by USD 57.68 million, or 6.19 percent.

Stock remains below its yearly high

BioMarin's Nasdaq range for the 52 weeks through October 16, 2026 was USD 49.26 to USD 70.98. The last price was 22.97 percent below the high and 11.00 percent above the low. The stock's year-to-date performance was minus 7.99 percent, with 2,627,298 shares traded against an average volume of 2,141,632.

Valuation and earnings date

BioMarin had a market capitalization of USD 10.6 billion and a trailing P/E ratio of 140.21 as of October 16, 2026. The next earnings date is October 26, 2026, according to Yahoo Finance. The upcoming report gives investors a near-term date for testing whether revenue growth can offset the stock's high earnings multiple.

Comparison with peers

BioMarin: minus 2.44 percent, P/E 140.21, market capitalization USD 10.6 billion
Vertex Pharmaceuticals (Nasdaq, USD): minus 1.77 percent, P/E 29.09, market capitalization USD 126.7 billion
Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E minus 5.90, market capitalization USD 1.8 billion

The stock's market position

BioMarin's USD 54.68 Nasdaq quote on October 16, 2026 at 4:00 p.m. EDT placed the company below its 52-week high and above its 52-week low. The next scheduled earnings date is October 26, 2026, while the UBS target of USD 88.00 provides the clearest dated analyst reference in the current market picture.

Market context: Market report Nasdaq Composite.

More news and analyses on BioMarin Pharmaceutical stock